BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:  Tuesday, August 6, 2024
Time: 8:30 AM Eastern Time
United States: 1-877-300-8521
International: 1-412-317-6026
Israel: 1-80-921-2373
Conference ID: 10190847
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1679332&tp_key=1f7beb24a2
   

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts: 
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com

Staff

Recent Posts

Waystar to Present at Goldman Sachs Communacopia + Technology Conference

LEHI, Utah and LOUISVILLE, Ky., Aug. 26, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider…

1 hour ago

Waters Corporation to Present at the Wells Fargo Healthcare Conference

MILFORD, Mass., Aug. 26, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters…

1 hour ago

GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company…

1 hour ago

Red Rover Health Celebrated in KLAS Research’s Emerging Company Spotlight Report

DES MOINES, Iowa, Aug. 26, 2025 /PRNewswire/ -- KLAS Research has released its latest Emerging Company…

1 hour ago

Unisom® Teams Up with Football Legend Julian Edelman to Help Fantasy Football Fans Get a Better Night’s Rest

The brand launches Sleeper Pickz in partnership with Julian Edelman to help fans put fantasy…

1 hour ago

TheChallenge.org: New Study by Finds Reducing Phone Use is Over Twice as Hard as Enduring a Daily Ice Bath

WARSAW, Poland, Aug. 26, 2025 /PRNewswire/ -- A new social study involving 9,150 participants from…

1 hour ago